1. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Issue 4 (April 2021) Authors: Guigay, Joël; Aupérin, Anne; Fayette, Jérôme; Saada-Bouzid, Esma; Lafond, Cédrik; Taberna, Miren; Geoffrois, Lionnel; Martin, Laurent; Capitain, Olivier; Cupissol, Didier; Castanie, Hélène; Vansteene, Damien; Schafhausen, Philippe; Johnson, Alison; Even, Caroline; Sire, Christian; Duplomb, Sophie... Journal: Lancet oncology Issue: Volume 22:Issue 4(2021) Page Start: 463 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗